Microbot Medical Narrows Q2 Loss Amidst Continued R&D Investment

TL;DR

MBOT is burning cash with no revenue, so unless you're betting on a miracle robot, stay away.

AI Summary

Microbot Medical Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, as the company remains in the development stage. The net loss for the three months ended June 30, 2025, was $3.8 million, a decrease from a net loss of $4.1 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $7.6 million, compared to $8.1 million for the six months ended June 30, 2024. This represents a 7.3% decrease in net loss for the six-month period. Key business changes include continued investment in research and development, with R&D expenses at $2.2 million for the three months ended June 30, 2025, and $4.4 million for the six months ended June 30, 2025. The company raised capital through an At-The-Market Offering Program and private placements, increasing additional paid-in capital by $1.1 million in Q1 2025 and $0.7 million in Q2 2025. The strategic outlook focuses on advancing its robotic medical device technology, particularly the Liberty® Robotic System, towards commercialization, though significant capital will be required.

Why It Matters

For investors, Microbot Medical's continued lack of revenue and reliance on capital raises for operations signal high risk, despite a slight reduction in net loss. The company's progress with the Liberty® Robotic System is critical, but its competitive position against larger, established medical device companies remains challenging. Employees face job security tied to successful product development and funding, while potential customers await a viable, market-ready product. The broader market for robotic surgery is growing, but MBOT's ability to capture market share depends entirely on successful clinical trials and regulatory approval, which are still distant.

Risk Assessment

Risk Level: high — Microbot Medical Inc. reported no revenue for the three and six months ended June 30, 2025, and a net loss of $7.6 million for the six months ended June 30, 2025. The company's accumulated deficit was $177.3 million as of June 30, 2025, indicating significant historical losses and a high dependency on future capital raises to fund operations and product development.

Analyst Insight

Investors should avoid MBOT given its pre-revenue status, substantial accumulated deficit, and ongoing need for external financing. Only speculative investors with a high-risk tolerance and belief in the long-term potential of its robotic technology should consider a position, understanding the high probability of further dilution.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$3.8M

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

0.0%

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue for Q2 2025 or YTD 2025, indicating pre-commercial stage.)
• $3.8M — Net Loss (Q2 2025) (Decreased from $4.1M in Q2 2024, showing a slight improvement in loss management.)
• $7.6M — Net Loss (YTD 2025) (Decreased from $8.1M in YTD 2024, a 7.3% reduction in loss.)
• $4.4M — R&D Expenses (YTD 2025) (Continued significant investment in product development, crucial for future revenue.)
• $177.3M — Accumulated Deficit (As of June 30, 2025, highlighting substantial historical losses and capital needs.)
• $1.8M — Capital Raised (YTD 2025) (Through ATM and private placements, essential for funding operations.)

Key Players & Entities

• Microbot Medical Inc. (company) — filer of the 10-Q
• Liberty® Robotic System (company) — key product under development
• $3.8 million (dollar_amount) — net loss for Q2 2025
• $4.1 million (dollar_amount) — net loss for Q2 2024
• $7.6 million (dollar_amount) — net loss for six months ended June 30, 2025
• $8.1 million (dollar_amount) — net loss for six months ended June 30, 2024
• $2.2 million (dollar_amount) — R&D expenses for Q2 2025
• $4.4 million (dollar_amount) — R&D expenses for six months ended June 30, 2025
• $1.1 million (dollar_amount) — increase in additional paid-in capital in Q1 2025
• $0.7 million (dollar_amount) — increase in additional paid-in capital in Q2 2025

FAQ

Risk Factors

• Substantial Accumulated Deficit [high — financial]: As of June 30, 2025, Microbot Medical Inc. has an accumulated deficit of $177.3 million. This indicates significant historical losses and a continued need for substantial capital to fund operations and achieve profitability.
• Development Stage and Commercialization Risk [high — operational]: The company remains in the development stage, with no revenue reported for the three and six months ended June 30, 2025. The successful commercialization of its robotic medical device technology, particularly the Liberty® Robotic System, is not guaranteed and requires significant future investment and market acceptance.
• Reliance on Capital Raising [medium — financial]: Microbot Medical Inc. has relied on capital raising activities, including an At-The-Market Offering Program and private placements, to fund its operations. The company raised $1.8 million in the first six months of 2025. Continued access to capital is critical for its ongoing development and eventual commercialization efforts.
• Regulatory Approval Pathway [medium — regulatory]: As a medical device company, Microbot Medical Inc. is subject to stringent regulatory approvals (e.g., FDA in the US). Delays or failures in obtaining necessary regulatory clearances for its Liberty® Robotic System could significantly impact its timeline to market and financial performance.
• Intense Competition [medium — operational]: The medical device industry, particularly in robotic surgery, is highly competitive. Microbot Medical Inc. faces competition from established players and emerging companies, which could affect market share and pricing power upon commercialization.

Industry Context

The medical device industry, particularly the segment focused on robotic surgical systems, is characterized by high R&D investment, long development cycles, and stringent regulatory oversight. Companies in this space compete on technological innovation, clinical efficacy, and market adoption. The trend is towards minimally invasive procedures, driving demand for advanced robotic solutions.

Regulatory Implications

As a developer of medical devices, Microbot Medical Inc. is subject to rigorous regulatory scrutiny from bodies like the FDA. Successful navigation of the approval process is paramount for commercialization. Any delays or failures in obtaining regulatory clearance for its Liberty® Robotic System could significantly impede market entry and revenue generation.

What Investors Should Do

1. Monitor R&D Milestones and Regulatory Updates
2. Assess Capital Needs and Funding Strategy
3. Evaluate Competitive Landscape

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q filing, showing continued development stage with no revenue and a net loss of $3.8 million for the quarter.
• 2025-08-12: 10-Q Filing Date — Official filing date for the quarterly report, providing investors with the latest financial and operational updates.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total amount of money a company has lost over its lifetime. (Indicates the company's historical unprofitability and significant capital requirements, standing at $177.3 million as of June 30, 2025.)

At-The-Market Offering Program (ATM)

A type of equity offering where a company sells shares of its stock on a stock exchange over a period of time at prevailing market prices. (Microbot Medical Inc. utilized this program to raise capital, contributing to the $1.8 million raised in the first six months of 2025.)

Development Stage

A classification for companies that have no active business operations or have not generated significant revenue, typically focusing on research and development of products or services. (Microbot Medical Inc. is in this stage, explaining the absence of revenue and the focus on R&D expenses.)

Liberty® Robotic System

Microbot Medical Inc.'s flagship robotic medical device technology currently under development. (This is the primary product the company aims to commercialize, and its progress is key to future revenue generation.)

Year-Over-Year Comparison

Compared to the prior year periods, Microbot Medical Inc. continues to report no revenue for the three and six months ended June 30, 2025, indicating its ongoing development stage. The net loss has slightly decreased, with the six-month period showing a 7.3% reduction in net loss ($7.6 million in 2025 vs. $8.1 million in 2024). R&D expenses remain a significant focus. Capital raised through ATM and private placements in the first half of 2025 ($1.8 million) is crucial for funding operations, similar to previous periods.

Filing Documents

• form10-q.htm (10-Q) — 740KB
• ex4-1.htm (EX-4.1) — 19KB
• ex31-1.htm (EX-31.1) — 19KB
• ex31-2.htm (EX-31.2) — 20KB
• ex32-1.htm (EX-32.1) — 6KB
• ex32-2.htm (EX-32.2) — 6KB
• 0001641172-25-023206.txt ( ) — 3995KB
• mbot-20250630.xsd (EX-101.SCH) — 31KB
• mbot-20250630_cal.xml (EX-101.CAL) — 31KB
• mbot-20250630_def.xml (EX-101.DEF) — 116KB
• mbot-20250630_lab.xml (EX-101.LAB) — 286KB
• mbot-20250630_pre.xml (EX-101.PRE) — 207KB
• form10-q_htm.xml (XML) — 528KB

- Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations 15

- Quantitative and Qualitative Disclosures About Market Risk

Item 3 - Quantitative and Qualitative Disclosures About Market Risk 20

- Controls and Procedures

Item 4 - Controls and Procedures 21

- Other Information

Part II - Other Information 22

- Legal Proceedings

Item 1 - Legal Proceedings 22

- Risk Factors

Item 1A - Risk Factors 22

- Unregistered Sales of Equity Securities and Use of Proceeds

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds 22

- Defaults Upon Senior Securities

Item 3 - Defaults Upon Senior Securities 22

- Mine Safety Disclosures

Item 4 - Mine Safety Disclosures 22

- Other Information

Item 5 - Other Information 22

- Exhibits

Item 6 - Exhibits 23

Signatures

Signatures 24 i MICROBOT MEDICAL INC. Interim Condensed Consolidated Balance Sheets U.S. dollars in thousands (Except share and per share data) As of As of Notes June 30, 2025 December 31, 2024 Unaudited Audited ASSETS Current assets: Cash and cash equivalents $ 4,082 $ 3,114 Marketable securities 2 28,592 2,356 Restricted cash 53 49 Prepaid expenses and other current assets 164 300 Total current assets 32,891 5,819 Property and equipment, net 75 80 Operating right-of-use assets 165 132 Total assets $ 33,131 $ 6,031 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 503 $ 165 Lease liabilities 102 70 Accrued liabilities 2,122 2,225 Total current liabilities 2,727 2,460 Non-current liabilities: Long-term lease liabilities 47 41 Total liabilities 2,774 2,501 Shareholders' equity: Common stock; $ 0.01 par value; 120,000,000 and 60,000,000 shares authorized as of June 30, 2025 and December 31, 2024, respectively; 37,958,316 and 19,399,513 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively. 380 195 Additional paid-in capital 127,022 94,279 Accumulated deficit ( 97,045 ) ( 90,944 ) Total shareholders' equity 30,357 3,530 Total liabilities and shareholders' equity $ 33,131 $ 6,031 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 1 MICROBOT MEDICAL INC. Interim Condensed Consolidated Statements of Comprehensive Loss U.S. dollars in thousands 2025 2024 2025 2024 For the Three Months Ended June 30, For the Six Months Ended June 30, 2025 2024 2025 2024 Unaudited Unaudited Research and development, net $ ( 2,111 ) $ ( 1,417 ) $ ( 3,570 ) $ ( 2,586 ) General and administrative ( 1,612 ) ( 1,094 ) ( 3,174 ) ( 2,309 ) Operating loss ( 3,723 ) ( 2,511 ) ( 6,744 ) ( 4,895 ) Other income (s

Risk Factors

Risk Factors To date, the Company has not generated revenues from its operations. As of June 30, 2025, the Company had cash equivalents and marketable securities balance of approximately $ 32,674 , excluding restricted cash. Due to continuing research and development and pre-commercialization activities, the Company expects to continue to incur additional losses for the foreseeable future. Notwithstanding these conditions, the Company's management has concluded that the available funds as of the balance sheet date, combined with the capital raises completed as described in Note 4, are sufficient to fund the Company's operations for more than twelve months from the issuance date of these financial statements. The Company expects to raise additional funds through future issuances of either debt and/or equity securities, including upon the cash exercise of outstanding investment options, and additional grants from the Israeli Innovation Authority and other government institutions. The Company's ability to raise additional capital in the equity and debt markets is dependent on a number of factors, including, but not limited to, the market demand for the Company's stock, which itself is subject to a number of development and business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company. Israel-Hamas War On October 7, 2023, the State of Israel, where our research and development and other operations are primarily based, suffered a surprise attack by hostile forces from Gaza, which led to Israeli military operation at first in Gaza and then in Lebanon. These military operations and related activities, such as the recent collapse of the Assad regime in Syria and Israel's subsequent military operations in Syria, and the recent escalation of military operations by and against the Houthis in Yemen and the Iranian regime, are on-going as of the issuanc

financial statements should be read in conjunction with the Company's latest audited financial statements

financial statements should be read in conjunction with the Company's latest audited financial statements. Operating results for the three and six-month period ended June 30, 2025, are not necessarily indicative of the results that may be expected for the year ending December 31, 2025. NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the Company's latest annual audited financial statements, except if noted below. Basis of presentation : The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("US GAAP"). Use of estimates : The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management's best judgment, actual results may differ from these estimates. Fair value of financial instruments : The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1 - Quoted prices (unadjusted) in active markets for identical assets and liabilities. Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, un

View Full Filing

View this 10-Q filing on SEC EDGAR